Recognizing and Treating Alzheimer S Disease

Recognizing and Treating Alzheimer S Disease

Recognizing and Treating Alzheimer’s Disease

Moving Towards Early Diagnosis and Disease Management

Additional Reading

  1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270-279.
  2. Alzheimer’s Association. Alzheimer’s Association Report: 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2015;11:332-384. Full report available at:
  3. Alzheimer's Disease International. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. Available at
  4. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-273.
  5. Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23:306-314.
  6. Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9:141-150.
  7. Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol. 2015;2:307-323.
  8. Cummings J, Cho W, Ward M, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimers Dement. 2014;10(4 Suppl):P275 (Abstract O4-11-06).
  9. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311-321.
  10. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer’s Association guidelines for the neuropathic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1-13.
  11. Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
  12. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimer’s Dement. 2013;9:e1-e16.
  13. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer’s disease. Cold Spring Harb Perspect Med. 2012;2:a006213.
  14. Lin JS, O'Connor E, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available at www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063382/pdf/PubMedHealth_PMH0063382.pdf
  15. Liu-Seifert H, Siemers E, Holdridge KC, et al. Delayed-start analysis: mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimers Dement Transl Res Clin Interventions. 2015;1:111-121.
  16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263-269.
  17. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322-333.
  18. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):280–92.
  19. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimer's Res Ther. 2014; 6:89.

Websites

Alzheimer’s Association,

Alzheimer’s Foundation of America,

Family Caregiver Alliance,

Alzheimer’s Disease Education and Referral Center, National Institute on Aging, https://www.nia.nih.gov/alzheimers

Alzheimer’s Disease International,

For more information, please visit

Top View